New News information at Pharmaceutical Technology New and updated information from News listed on www.pharmaceutical-technology.com http://www.pharmaceutical-technology.com/ en-us http://www.pharmaceutical-technology.com/ New News information at Pharmaceutical Technology http://www.pharmaceutical-technology.com/content/images/logo_big.gif US FDA awards orphan drug designation to Minoryx’s MIN-102 compound http://www.pharmaceutical-technology.com/news/newsus-fda-awards-orphan-drug-designation-to-minoryxs-min-102-compound-5748808 http://www.pharmaceutical-technology.com/news/newsus-fda-awards-orphan-drug-designation-to-minoryxs-min-102-compound-5748808 The US Food and Drug Administration (FDA) has granted orphan drug designation to Minoryx Therapeutics’ lead compound MIN-102. Fri, 24 Feb 2017 00:00:00 GMT M&As this week: Zhejiang Conba Pharmaceutical, Biolennia Laboratories http://www.pharmaceutical-technology.com/news/newsmas-this-week-zhejiang-conba-pharmaceutical-co-ltd-biolennia-laboratories-inc-5748353 http://www.pharmaceutical-technology.com/news/newsmas-this-week-zhejiang-conba-pharmaceutical-co-ltd-biolennia-laboratories-inc-5748353 Zhejiang Conba Pharmaceutical has sold 57.3% stake in a pharmaceutical company for ¥345.1m ($50.27m). Fri, 24 Feb 2017 00:00:00 GMT Deals this week: Affigen, Albany Molecular Research, Bristol-Myers Squibb http://www.pharmaceutical-technology.com/news/newsdeals-this-week-affigen-llc-albany-molecular-research-inc-bristol-myers-squibb-5748315 http://www.pharmaceutical-technology.com/news/newsdeals-this-week-affigen-llc-albany-molecular-research-inc-bristol-myers-squibb-5748315 In a series A venture financing round, US-based biotechnology company Affigen has raised $17m to be utilised for advancing the company’s lead programmes in a number of haematological malignancies through pre-clinical validation and into phase I clini… Fri, 24 Feb 2017 00:00:00 GMT Abivax to screen new antiviral molecules to develop therapeutic candidates against dengue fever http://www.pharmaceutical-technology.com/news/newsabivax-to-screen-new-antiviral-molecules-to-develop-therapeutic-candidates-against-dengue-5748878 http://www.pharmaceutical-technology.com/news/newsabivax-to-screen-new-antiviral-molecules-to-develop-therapeutic-candidates-against-dengue-5748878 French biotechnology company Abivax has discovered new antiviral molecules and is screening them to develop therapeutic candidates against dengue fever. Fri, 24 Feb 2017 00:00:00 GMT Valeant and EyeGate sign licensing agreement http://www.pharmaceutical-technology.com/news/newsvaleant-and-eyegate-sign-licencing-agreement-5747680 http://www.pharmaceutical-technology.com/news/newsvaleant-and-eyegate-sign-licencing-agreement-5747680 Valeant Pharmaceuticals has signed an agreement for global commercial and manufacturing rights to US-based EyeGate Pharmaceuticals’ new technology and EGP-437 combination product candidate to treat post-operative pain and inflammation in occular surg… Thu, 23 Feb 2017 00:00:00 GMT US FDA accepts regulatory submission for Pfizer’s inotuzumab ozogamicin http://www.pharmaceutical-technology.com/news/newsus-fda-accepts-regulatory-submission-for-pfizers-inotuzumab-ozogamicin-5746156 http://www.pharmaceutical-technology.com/news/newsus-fda-accepts-regulatory-submission-for-pfizers-inotuzumab-ozogamicin-5746156 US-based pharmaceutical company Pfizer’s biologics licence application (BLA) for inotuzumab ozogamicin has been accepted for filing and granted priority review by the US Food and Drug Administration (FDA). Thu, 23 Feb 2017 00:00:00 GMT Northwell Health and GE Ventures collaborate to research bioelectronic medicine http://www.pharmaceutical-technology.com/news/newsnorthwell-health-ge-ventures-collaborate-to-research-on-bioelectronic-medicine-5746417 http://www.pharmaceutical-technology.com/news/newsnorthwell-health-ge-ventures-collaborate-to-research-on-bioelectronic-medicine-5746417 US-based healthcare network Northwell Health's Feinstein Institute for Medical Research has entered a strategic alliance with GE Ventures to support the institute’s Center for Bioelectronic Medicine (CBEM). Thu, 23 Feb 2017 00:00:00 GMT AstraZeneca and TerSera sign agreement to commercialise Zoladex in US and Canada http://www.pharmaceutical-technology.com/news/newsastrazeneca-and-tersera-sign-agreement-to-commercialise-zoladex-in-us-and-canada-5745187 http://www.pharmaceutical-technology.com/news/newsastrazeneca-and-tersera-sign-agreement-to-commercialise-zoladex-in-us-and-canada-5745187 UK-based AstraZeneca has entered an agreement to sell the commercial rights for Zoladex (goserelin acetate implant) in the US and Canadian markets to pharmaceutical company TerSera Therapeutics. Wed, 22 Feb 2017 00:00:00 GMT Neovacs and BioSense partner to develop and commercialise IFNa Kinoid in China http://www.pharmaceutical-technology.com/news/newsneovacs-and-biosense-sign-agreement-for-development-and-commercialisation-of-ifn-kinoid-in-china-5746084 http://www.pharmaceutical-technology.com/news/newsneovacs-and-biosense-sign-agreement-for-development-and-commercialisation-of-ifn-kinoid-in-china-5746084 French-based Neovacs has signed a commercial licence option agreement with BioSense Global for the development and commercial rights of IFNα Kinoid vaccine to treat lupus and dermatomyositis in China. Wed, 22 Feb 2017 00:00:00 GMT US FDA grants fast-track designation to Cell Medica's CMD-003 http://www.pharmaceutical-technology.com/news/newsus-fda-grants-fast-track-designation-for-cell-medicas-cmd-003-5745327 http://www.pharmaceutical-technology.com/news/newsus-fda-grants-fast-track-designation-for-cell-medicas-cmd-003-5745327 The US Food and Drug Administration (FDA) has granted fast-track designation to UK-based cellular immunotherapy firm Cell Medica's oncology product CMD-003 (baltaleucel-T). Wed, 22 Feb 2017 00:00:00 GMT Recipharm acquires Kemwell’s pharmaceutical businesses in India for $118.5m http://www.pharmaceutical-technology.com/news/newsrecipharm-acquires-kemwells-pharmaceutical-businesses-in-india-for-1185m-5744909 http://www.pharmaceutical-technology.com/news/newsrecipharm-acquires-kemwells-pharmaceutical-businesses-in-india-for-1185m-5744909 Sweden's Recipharm has completed the previously announced acquisition of Kemwell’s pharmaceutical businesses in Bengaluru, India, in a deal valued at Skr1.05bn ($118.5m). Tue, 21 Feb 2017 00:00:00 GMT Mereo BioPharma’s BPS-804 drug accepted for participation in EMA’s adaptive pathways programme http://www.pharmaceutical-technology.com/news/newsmereo-biopharmas-bps-804-drug-accepted-for-participation-in-emas-adaptive-pathways-programme-5744926 http://www.pharmaceutical-technology.com/news/newsmereo-biopharmas-bps-804-drug-accepted-for-participation-in-emas-adaptive-pathways-programme-5744926 UK-based biopharmaceutical company Mereo BioPharma has announced that its BPS-804 drug has been accepted to participate in the European Medicines Agency’s (EMA) adaptive pathways programme. Tue, 21 Feb 2017 00:00:00 GMT Sobi renews Ammonul distribution agreement with Valeant Pharmaceuticals http://www.pharmaceutical-technology.com/news/newssobi-renews-ammonul-distribution-agreement-with-valeant-5744875 http://www.pharmaceutical-technology.com/news/newssobi-renews-ammonul-distribution-agreement-with-valeant-5744875 Healthcare firm Swedish Orphan Biovitrum (Sobi) has entered a new three-year agreement with Valeant Pharmaceuticals Ireland to distribute Ammonul (sodium phenyl acetate and sodium benzoate) injection in Europe, the Middle East and North Africa. Tue, 21 Feb 2017 00:00:00 GMT US researchers find vitamin B3 prevents glaucoma http://www.pharmaceutical-technology.com/news/newsus-researchers-say-vitamin-b3-prevents-glaucoma-5743923 http://www.pharmaceutical-technology.com/news/newsus-researchers-say-vitamin-b3-prevents-glaucoma-5743923 Researchers from The Jackson Laboratory (JAX), US, have found that vitamin B3, when added to drinking water, is effective at preventing glaucoma. Mon, 20 Feb 2017 00:00:00 GMT Amygdala Neurosciences to acquire GS-6637 from Gilead Sciences http://www.pharmaceutical-technology.com/news/newsamygdala-neurosciences-to-acquire-gs-6637-from-gilead-sciences-5743998 http://www.pharmaceutical-technology.com/news/newsamygdala-neurosciences-to-acquire-gs-6637-from-gilead-sciences-5743998 US-based Amygdala Neurosciences has signed an agreement to acquire GS-6637, a ALDH2 inhibitor from Gilead Sciences. Mon, 20 Feb 2017 00:00:00 GMT Novartis and NHS Ayrshire & Arran launch new eye care facility in Scotland http://www.pharmaceutical-technology.com/news/newsnovartis-and-nhs-ayrshire-arran-launch-new-eye-care-facility-in-scotland-5743936 http://www.pharmaceutical-technology.com/news/newsnovartis-and-nhs-ayrshire-arran-launch-new-eye-care-facility-in-scotland-5743936 Novartis Pharmaceuticals UK and NHS Ayrshire & Arran have announced the launch of a new facility designed specifically for people suffering from some of the most common forms of avoidable sight loss. Mon, 20 Feb 2017 00:00:00 GMT Is digital disruption of heart disease markets on the horizon? http://www.pharmaceutical-technology.com/news/newsis-digital-disruption-of-heart-disease-markets-on-the-horizon-5743139 http://www.pharmaceutical-technology.com/news/newsis-digital-disruption-of-heart-disease-markets-on-the-horizon-5743139 February, the American Heart Month, has seen the American Heart Association (AHA) announcing a plan to team up with IBM Watson Health, the cognitive system division of IBM Corporation. Fri, 17 Feb 2017 14:42:00 GMT Cutting costs but not quality: heart failure hospitalisations http://www.pharmaceutical-technology.com/news/newscutting-costs-but-not-quality-heart-failure-hospitalisations-5743129 http://www.pharmaceutical-technology.com/news/newscutting-costs-but-not-quality-heart-failure-hospitalisations-5743129 Over one million Americans are hospitalized for heart failure (HF) each year. This results in a poor prognosis for patients and places a significant financial burden on the US healthcare system. Fri, 17 Feb 2017 14:34:00 GMT Vedanta, Stanford and Leiden universities partner to study food allergies in children http://www.pharmaceutical-technology.com/news/newsvedanta-stanford-and-leiden-universities-partner-to-study-food-allergies-in-children-5742726 http://www.pharmaceutical-technology.com/news/newsvedanta-stanford-and-leiden-universities-partner-to-study-food-allergies-in-children-5742726 US-based Vedanta Biosciences has collaborated with Stanford University School of Medicine and Leiden University Medical Center to study food allergies in children and patients with C difficile infection or graft-versus-host disease, respectively. Fri, 17 Feb 2017 00:00:00 GMT Deals this week: Xiangxue Pharmaceutical, Auris Medical Holding, Enzymatica http://www.pharmaceutical-technology.com/news/newsdeals-this-week-xiangxue-pharmaceutical-co-ltd-auris-medical-holding-ag-enzymatica-ab-5742212 http://www.pharmaceutical-technology.com/news/newsdeals-this-week-xiangxue-pharmaceutical-co-ltd-auris-medical-holding-ag-enzymatica-ab-5742212 Xiangxue Pharmaceutical intends to raise up to ¥1.2bn ($188.47m) in a public offering of bonds. Fri, 17 Feb 2017 00:00:00 GMT